Dive Brief:
- Erasca said that 44% of people with KRAS-mutated pancreatic cancer responded to its experimental treatment in a small Phase 1 trial, supporting a decision to quickly advance the medicine into a Phase 3 study.
- According to Erasca, response rates to its drug ERAS-0015 were even higher — 63% and 80%, respectively — in people with specific KRAS mutations called G12D and G12V. Those genetic signatures cover around two-thirds of people with KRAS-mutated disease. Side effects were mostly mild, and nobody quit treatment because of them, the company added.
- While early, the data suggest Erasca’s drug could emerge as a future threat to Revolution Medicines’ breakthrough medicine Rasonque, which has already changed how pancreatic cancer is treated. Revolution’s therapy is already on the market and off to one of the best oncology launches ever. But Rasonque is associated with frequent skin rashes and its impact on G12D-mutated patients is seen as modest, leaving an opening for competitors to exploit.
Dive Insight:
Drug research directed at tumors driven by mutations to a family of genes known as “RAS” is advancing quickly. Once seen as “undruggable,” RAS-targeting medicines are now the focus of a constellation of would-be treatments vying to build on Revolution’s success.
Erasca is one of those followers. Like Rasonque, ERAS-0015 is a “molecular glue” that blocks cancer cells from growing and spreading. But it’s designed to have potentially superior characteristics. Erasca is testing it in pancreatic, biliary tract and non-small cell lung cancers.
In initiating coverage of Erasca earlier this week, Leerink Research analyst Asthika Goonewardene wrote that ERAS-0015’s lower side effect rate, if confirmed in additional testing, could offer “opportunities to carve out niches that Rasonque may not be able to access” because of Rasonque’s “overlapping toxicities” with other medicines.
Friday’s data offer an early glimpse of that potential. Unveiled at a medical meeting, the results come from a study of 122 people whose pancreatic cancer had progressed following two or more treatment lines. Study volunteers received daily doses ranging from 16 to 32 milligrams.
ERAS-0015’s response rates were higher than what’s been seen in testing of Rasonque. Revolution’s drug led to treatment responses in 32% of the overall study population and 24% and 50%, respectively, in people with G12D and G12V mutations. Cross-trial comparisons are error-prone, however, and the two drugs haven’t been tested head-to-head.
Still, the data suggest ERAS-0015 “could be a formidable competitor in the future, and potentially accelerate the fragmentation of the RAS landscape,” wrote RBC Capital Markets analyst Leonid Timashev, who covers Revolution, in a client note. The drug “continues to demonstrate a better profile on both efficacy and safety in what was a challenging population — suggesting what may be real differentiation.”
TD Cowen analyst Tyler Van Buren disagreed, contending in a separate note that it’s unclear whether the early results will translate to a superior profile in a bigger trial. Oncologists are getting better at managing Rasonque’s side effects, too. Erasca’s data “fail to meaningfully differentiate from Rasonque, especially considering the multi-year commercial head start Rasonque has on nearest competitors,” he wrote.
Revolution, meanwhile, released new data from an early-stage trial testing Rasonque alongside chemotherapy in frontline pancreatic cancer. The combination drove responses in 61% of enrollees, and 8% had no evidence of active disease.
Another RAS-focused company, Alterome Therapeutics, presented data from a trial testing its drug ALTA3263 in combination with Erbitux. The pairing stimulated responses in 31% of people with KRAS-mutated colorectal cancer.